Clinical-stage monoclonal antibodies targeting the CD40-CD40L axis have shown efficacy in autoimmune disorders [58], offering a precision strategy to suppress pathological immune responses while potentially mitigating irAEs. This evidence concerns the gene CD40LG and autoimmune disease.